Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
The aim of this single-arm phase 2 clinical trial is to evaluate the anti-cancer activity of
Talazoparib (also known as BMN 673) in patients with advanced breast cancer with specific
genetic or tumor genomic alterations. Patients with either triple-negative or HER2-negative
breast cancer are eligible.
Phase:
Phase 2
Details
Lead Sponsor:
Melinda Telli
Collaborators:
BioMarin Pharmaceutical National Cancer Institute (NCI) Pfizer